Diabetes Care. 2000 Aug;23(8):1084-91. doi: 10.2337/diacare.23.8.1084.
To assess the effect of pregnancy on the development and progression of retinopathy and microalbuminuria in type 1 diabetes.
We conducted longitudinal analyses of the Diabetes Control and Complications Trial (DCCT), a multicenter controlled clinical trial that compared intensive treatment with conventional diabetes therapy and studied 180 women who had 270 pregnancies and 500 women who did not become pregnant during an average of 6.5 years of follow-up. Women assigned to the conventional treatment group were changed to intensive therapy if they were planning pregnancy or as soon as possible after conception. Fundus photography was performed every 6 months, and the urinary albumin excretion rate (AER) was measured annually.
Compared with nonpregnant women, pregnant women had a 1.63-fold greater risk of any worsening of retinopathy from before to during pregnancy (P < 0.05) in the intensive treatment group; the risk was 2.48-fold greater for pregnant vs. not pregnant women in the conventional group (P < 0.001). In the conventional group, the odds of > or =3-step progression from the baseline retinopathy level was >2.9-fold among pregnant vs. not pregnant women (P = 0.003). The odds ratio (OR) peaked during the second trimester (OR = 4.26, P = 0.001) and persisted as long as 12 months postpregnancy (OR = 2.87, P = 0.005). The level of AER during pregnancy in the intensive group, but not in the conventional group, was significantly elevated from the level at baseline, albeit in the normal range. Although individual patients had transient worsening of retinopathy during pregnancy, even to the proliferative level, at the end of the DCCT, mean levels of retinopathy and albuminuria in subjects who had become pregnant were similar to those in subjects who had not become pregnant within each treatment group.
Pregnancy in type 1 diabetes induces a transient increase in the risk of retinopathy; increased ophthalmologic surveillance is needed during pregnancy and the first year postpartum. The long-term risk of progression of early retinopathy and albumin excretion, however, does not appear to be increased by pregnancy.
评估妊娠对1型糖尿病视网膜病变和微量白蛋白尿的发生及进展的影响。
我们对糖尿病控制与并发症试验(DCCT)进行了纵向分析,这是一项多中心对照临床试验,比较了强化治疗与传统糖尿病治疗,并研究了180名有270次妊娠的女性以及500名在平均6.5年随访期间未怀孕的女性。分配到传统治疗组的女性如果计划怀孕或在受孕后尽快改为强化治疗。每6个月进行一次眼底照相,每年测量尿白蛋白排泄率(AER)。
与未怀孕女性相比,强化治疗组中怀孕女性从妊娠前到妊娠期间视网膜病变任何恶化的风险高1.63倍(P<0.05);在传统治疗组中,怀孕女性与未怀孕女性相比风险高2.48倍(P<0.001)。在传统治疗组中,怀孕女性与未怀孕女性相比,从基线视网膜病变水平进展≥3级的几率>2.9倍(P = 0.003)。优势比(OR)在孕中期达到峰值(OR = 4.26,P = 0.001),并持续至产后长达12个月(OR = 2.87,P = 0.005)。强化治疗组妊娠期间的AER水平虽仍在正常范围内,但与基线水平相比显著升高,而传统治疗组则不然。尽管个别患者在妊娠期间视网膜病变出现短暂恶化,甚至发展到增殖性水平,但在DCCT结束时,每个治疗组中已怀孕受试者的视网膜病变和白蛋白尿平均水平与未怀孕受试者相似。
1型糖尿病患者妊娠会导致视网膜病变风险短暂增加;妊娠期间及产后第一年需要加强眼科监测。然而,妊娠似乎并未增加早期视网膜病变进展和白蛋白排泄的长期风险。